YTD Revenues and Adjusted EBITDA1 Exceed Guidance

Forecasting Continued Strategic Growth

Newport Beach, CA - November 8, 2022 - American Vanguard Corporation (NYSE: AVD), today announced financial results for the third quarter and nine months ended September 30, 2022.

Financial Highlights Fiscal 2022 Third Quarter - versus Fiscal 2021 Third Quarter

• Net sales of $152 million in 2022, a 3.4% increase, compared with $147 million in 2021

• Net income of $6.7 million in 2022, a 21.8% increase, compared with $5.5 million in 2021

• Earnings per diluted share of $0.23 in 2022, a 27.8% increase, compared with $0.18 in 2021

• Adjusted EBITDA of $18.9 million in 2022, a 11.2% increase, compared with $17.0 million in 2021

Financial Highlights Fiscal 2022 Nine Months - versus Fiscal 2021 Nine Months

• Net sales of $450 million in 2022, a 13.1% increase, compared with $398 million in 2021

• Net income of $23.5 million in 2022, a 71.5% increase, compared with $13.7 million in 2021

• Earnings per diluted share of $0.78 in 2022, a 73.3% increase, compared with $0.45 in 2021

• Adjusted EBITDA of $61.4 million in 2022, a 29.8% increase, compared to $47.3 million in 2021

Eric Wintemute, Chairman and CEO of American Vanguard commented, "We achieved strong third quarter results and through the first nine months of 2022 and are on pace to meet or exceed our full year performance targets. High crop commodity prices, a strong farm economy and seasonal pest pressure (particularly in corn and cotton) fueled continued growth of our US Crop business. Similarly, our international business recorded strong sales, led by Brazil (particularly our Counter nematicide), Mexico (due largely to soil fumigant sales) and a range of products for use on bananas and pineapples in Central America. Partially offsetting these gains, we experienced a decrease in net sales of our domestic non-crop business, due largely to softening of consumer spending in the lawn and garden markets."

1

Adjusted earnings before interest, taxes, depreciation, amortization, non-cash stock compensation, and proxy contest activities. Adjusted EBITDA is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income (loss), operating income (loss) or any other financial measure so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. The items excluded from Adjusted EBITDA are detailed in the reconciliation attached to this news release. Other companies (including the Company's competitors) may define Adjusted EBITDA differently.

1

Mr. Wintemute continued, "Our year-to-date revenue performance exceeds the full-year 2022 growth target for net sales that we had set last March (13% actual growth v. 8-11% target), as does net income (71% actual growth v. 60-70% target) and adjusted EBITDA (30% actual growth v. 24-28% target). Faced with inflationary cost increases, supply chain challenges and high demand, we were able to implement appropriate price increases while maximizing factory activity. These factors contributed to higher net income as a percent of net sales for both the quarter and the first nine months. Additionally, we expect significant year-end debt reduction and a full-year adjusted EBITDA of approximately $80 million or 13% of expected sales. Finally, through a combination of an Accelerated Share Repurchase Plan and a 10b5-1 purchase plan, we acquired 1.5 million shares of AVD common stock during the first nine months of the year. These repurchases demonstrate our belief in the company's long-term value and serve to enhance shareholder investment."

Mr. Wintemute concluded, "We continue to pursue strategic growth initiatives to expand our core business and develop new technologies, with particular emphasis on Green Solutions and Precision Application innovations. As we announced over the past few weeks, we have established an alliance with NewLeaf Symbiotics, which will complement our existing portfolio of patented biological plant nutrients and soil health enrichments. In addition, we secured registration approval for use of our Counter nematicide on soybeans in Brazil, which will improve market penetration with a proprietary product, while advancing the adoption of SIMPAS prescription application technology in the largest Agricultural market in the world. We look forward to providing details on current business trends and these growth initiatives in our upcoming quarterly conference call."

Conference Call

Eric Wintemute, Chairman & CEO, Bob Trogele EVP & COO and David T. Johnson, VP & CFO, will conduct a conference call focusing on the financial results at 4:30 pm ET / 1:30 pm PT on Monday, November 8, 2022. Interested parties may participate in the call by dialing 201-493-6744 - please dial in 10 minutes before the call is scheduled to begin and ask for the American Vanguard call. The conference call will also be webcast live via the News and Media section of the Company's web site at www.american-vanguard.com. To listen to the live webcast, go to the web site at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, the conference call will be archived on the Company's web site.

About American Vanguard

American Vanguard Corporation is a diversified specialty and agricultural products company that develops and markets products for crop protection and management, turf and ornamentals management and public and animal health. American Vanguard is included on the Russell 2000® and Russell 3000® Indexes and the Standard & Poor's Small Cap 600 Index. To learn more about American Vanguard, please reference the Company's web site at www.american-vanguard.com.

2

The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this release, all forward-looking statements are estimates by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include weather conditions, changes in regulatory policy and other risks as detailed from time-to-time in the Company's SEC reports and filings. All forward-looking statements, if any, in this release represent the Company's judgment as of the date of this release.

Company Contact: Investor Representative

American Vanguard Corporation

William A. Kuser, Director of Investor Relations

(949) 260-1200

williamk@amvac.com

The Equity Group Inc.

www.theequitygroup.com

Lena Cati (212) 836-9611

Lcati@equityny.com

3

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

ASSETS September 30,
2022
December 31,
2021

Current assets:

Cash and cash equivalents

$ 20,808 $ 16,285

Receivables:

Trade, net of allowance for doubtful accounts of $4,535 and $3,938, respectively

194,515 149,326

Other

10,022 9,595

Total receivables, net

204,537 158,921

Inventories

192,309 154,306

Prepaid expenses

16,967 12,488

Income taxes receivable

2,180 -

Total current assets

436,801 342,000

Property, plant and equipment, net

68,598 66,111

Operating lease right-of-use assets

25,402 25,386

Intangible assets, net

187,207 197,841

Goodwill

46,215 46,260

Other assets

11,936 16,292

Deferred income tax assets, net

16 270

Total assets

$ 776,175 $ 694,160
LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Current installments of other liabilities

$ - $ 802

Accounts payable

81,919 67,140

Customer prepayments

222 63,064

Accrued program costs

108,016 63,245

Accrued expenses and other payables

24,390 20,745

Income taxes payable

- 3,006

Current operating lease liabilities

5,329 5,059

Total current liabilities

219,876 223,061

Long-term debt, net

148,414 52,240

Long-term operating lease liabilities

20,536 20,780

Other liabilities, net of current installments

5,457 5,335

Deferred income tax liabilities, net

19,324 20,006

Total liabilities

413,607 321,422

Commitments and contingent liabilities

Stockholders' equity:

Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued

- -

Common stock, $.10 par value per share; authorized 40,000,000 shares; issued

34,463,947 shares at September 30, 2022 and 34,248,218 shares at December 31, 2021

3,446 3,426

Additional paid-in capital

101,426 101,450

Accumulated other comprehensive loss

(15,532 ) (13,784 )

Retained earnings

325,698 304,385

Less treasury stock at cost, 4,884,200 shares at September 30, 2022 and 3,361,040 shares at December 31, 2021

(52,470 ) (22,739 )

Total stockholders' equity

362,568 372,738

Total liabilities and stockholders' equity

$ 776,175 $ 694,160

4

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

For the Three Months
Ended September 30,
For the Nine Months Ended
September 30,
2022 2021 2022 2021

Net sales

$ 152,117 $ 147,298 $ 449,636 $ 398,063

Cost of sales

(90,733 ) (90,234 ) (267,280 ) (243,729 )

Gross profit

61,384 57,064 182,356 154,334

Operating expenses

(50,140 ) (48,410 ) (145,550 ) (132,934 )

Adjustment to bargain purchase gain on business acquisition

- 292 - 171

Operating income

11,244 8,946 36,806 21,571

Change in fair value of equity investments

(454 ) (668 ) (857 ) 103

Other income

- - - 672

Interest expense, net

(1,086 ) (962 ) (2,256 ) (2,921 )

Income before provision for income taxes and loss on equity

method investment

9,704 7,316 33,693 19,425

Income tax expense

(2,963 ) (1,517 ) (10,187 ) (5,324 )

Income before loss on equity method investment

6,741 5,799 23,506 14,101

Loss on equity method investment

- (301 ) - (388 )

Net income

$ 6,741 $ 5,498 $ 23,506 $ 13,713

Earnings per common share-basic

$ .23 $ .18 $ .80 $ .46

Earnings per common share-assuming dilution

$ .23 $ .18 $ .78 $ .45

Weighted average shares outstanding-basic

29,214 29,892 29,496 29,854

Weighted average shares outstanding-assuming dilution

29,805 30,390 30,128 30,470

5

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

ANALYSIS OF SALES

(In thousands)

(Unaudited)

For the three months
ended September 30,
2022 2021 Change % Change

Net sales:

U.S. crop

$ 69,115 $ 66,722 $ 2,393 4 %

U.S. non-crop

18,936 21,622 (2,686 ) -12 %

U.S. total

88,051 88,344 (293 ) 0 %

International

64,066 58,954 5,112 9 %

Net sales:

$ 152,117 $ 147,298 $ 4,819 3 %

Gross profit:

U.S. crop

$ 34,502 $ 30,237 $ 4,265 14 %

U.S. non-crop

8,811 8,882 (71 ) -1 %

U.S. total

43,313 39,119 4,194 11 %

International

18,071 17,945 126 1 %

Total gross profit:

$ 61,384 $ 57,064 $ 4,320 8 %
For the nine months
ended September 30,
2022 2021 Change % Change

Net sales:

U.S. crop

$ 220,503 $ 184,052 $ 36,451 20 %

U.S. non-crop

53,648 60,563 (6,915 ) -11 %

U.S. total

274,151 244,615 29,536 12 %

International

175,485 153,448 22,037 14 %

Net sales:

$ 449,636 $ 398,063 $ 51,573 13 %

Gross profit:

U.S. crop

$ 104,599 $ 78,313 $ 26,286 34 %

U.S. non-crop

24,826 28,047 (3,221 ) -11 %

U.S. total

129,425 106,360 23,065 22 %

International

52,931 47,974 4,957 10 %

Total gross profit:

$ 182,356 $ 154,334 $ 28,022 18 %

6

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

For the Nine Months Ended
September 30,
2022 2021

Cash flows from operating activities:

Net income

$ 23,506 $ 13,713

Adjustments to reconcile net income to net cash used in operating

activities:

Depreciation and amortization of property, plant and equipment and intangible assets

16,649 17,045

Amortization of other long-term assets

2,656 2,981

Loss on disposal of property, plant and equipment

265 -

Accretion of discounted liabilities

28 (10 )

Amortization of deferred loan fees

174 294

Provision for bad debts

597 1,202

Loan principal and interest forgiveness

- (672 )

Fair value adjustment to contingent consideration

621 520

Stock-based compensation

4,396 5,309

Change in deferred income taxes

(64 ) (560 )

Change in fair value of equity investments

857 (103 )

Loss on equity method investment

- 388

Adjustment to bargain purchase gain on business acquisition

- (171 )

Net foreign currency adjustments

218 (330 )

Changes in assets and liabilities associated with operations:

Increase in net receivables

(46,289 ) (42,979 )

Increase in inventories

(38,987 ) (4,325 )

Increase in prepaid expenses and other assets

(4,272 ) (2,194 )

(Increase) decrease in income tax receivable/payable, net

(5,201 ) 2,031

Increase in net operating lease liability

10 183

Increase in accounts payable

14,418 7,769

Decrease in customer prepayments

(62,831 ) (38,272 )

Increase in accrued program costs

45,016 33,982

Increase in other payables and accrued expenses

2,555 4,025

Net cash used in operating activities

(45,678 ) (174 )

Cash flows from investing activities:

Capital expenditures

(8,946 ) (7,963 )

Proceeds from disposal of property, plant and equipment

46 -

Acquisition of product line

- (10,000 )

Intangible assets

(1,078 ) (285 )

Investments

- (183 )

Net cash used in investing activities

(9,978 ) (18,431 )

Cash flows from financing activities:

Payments under line of credit agreement

(64,000 ) (57,408 )

Borrowings under line of credit agreement

160,000 86,000

Payment of contingent consideration

- (250 )

Net receipt from the issuance of common stock under ESPP

837 743

Net receipt from the exercise of stock options

783 172

Payment for tax withholding on stock-based compensation awards

(2,020 ) (2,915 )

Repurchase of common stock

(33,731 ) (4,579 )

Payment of cash dividends

(2,072 ) (1,789 )

Net cash provided by financing activities

59,797 19,974

Net increase in cash and cash equivalents

4,141 1,369

Effect of exchange rate changes on cash and cash equivalents

382 (574 )

Cash and cash equivalents at beginning of period

16,285 15,923

Cash and cash equivalents at end of period

$ 20,808 $ 16,718

7

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

UNAUDITED RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA

Three Months Ended
September 30,
Nine Months Ended
September 30,
2022 2021 2022 2021

Net income, as reported

$ 6,741 $ 5,498 $ 23,506 $ 13,713

Provision for income taxes

2,963 1,517 10,187 5,324

Interest expense, net

1,086 962 2,256 2,921

Depreciation and amortization

6,562 7,285 19,305 20,026

Stock compensation

1,560 1,711 4,396 5,309

Proxy contest activities

- - 1,785 -

Adjusted EBITDA2

$ 18,912 $ 16,973 $ 61,435 $ 47,293
2

Adjusted earnings before interest, taxes, depreciation, amortization, non-cash stock compensation, and proxy contest activities. Adjusted EBITDA is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income (loss), operating income (loss) or any other financial measures so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. We provide these measures because we believe that they provide helpful comparisons to other companies in our industry and peer group. The items excluded from Adjusted EBITDA are detailed in the reconciliation attached to this news release. Other companies (including the Company's competitors) may define Adjusted EBITDA differently.

8

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

American Vanguard Corporation published this content on 10 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 November 2022 19:28:03 UTC.